期刊文献+

他克莫司滴眼液抑制家兔全角膜移植免疫排斥反应

Inhibiting effects of tacrolimus eye drops on immunological rejection reaction corneal transplantation in rabbit
下载PDF
导出
摘要 目的通过家兔全角膜移植动物实验,考察他克莫司滴眼液抑制家兔角膜移植免疫排斥反应的量效关系,为他克莫司滴眼液的临床应用提供实验依据。方法建立家兔全角膜移植排斥反应模型,随机分成A组、B组、C组、D组、E组和F组。其中A组为溶剂对照组,B组、C组、D组、E组质量分数分别为0.01%、0.025%、0.05%、0.1%的他克莫司滴眼液,F组为环孢霉A滴眼液。用裂隙灯记录比较各组排斥反应指数(rejection index,RI)和植片存活时间,连续给药28 d后摘取角膜进行组织学检查。结果术后B组、C组、D组、E组和F组各组与A组比较,角膜植片RI和植片存活时间均有显著差异(P<0.05或P<0.01),呈剂量-效应关系,淋巴细胞浸润及新生血管生成均明显减少。结论质量分数0.05%的他克莫司滴眼液可抑制家兔全角膜移植免疫排斥反应。 Objective To observe the effect of tacrolimus eye drops on immunological rejection after corneal transplantation in rabbit, and to provide some experimental basis for the clinical application of tacrolimus eye drops. Methods The animal model of total keratoplasty was established and the totally 36 rabbits randomly divided into six groups with 6 rabbits in each group. Untreated control rabbits were placed in A group, and rabbits treated with cyclosporine A were placed in F group. The rabbits administered with 0. 01% ,0. 025%, 0. 05% ,0. 1% tacrolimus eye drop were placed in B to E group successively. The corneal survival time and rejection reaction index ( RI ) were recorded. After 28 days of continuous treatment, the rabbits corneal histological were examed. Results The RI and survival time of the corneal grafts in each treated group were significantly different as compared with the control group ( P 〈 0.05 or P 〈 0. 01 ). The phenomenon of lymphocyte infiltration and neovascularization was significantly reduced. Conclusions Tacrolimus eye drops with concentration of 0. 05% dose can prevent the rejection reaction after therapeutic total keratoplasty in rabbit effectively.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2016年第1期63-66,共4页 Journal of Shenyang Pharmaceutical University
关键词 他克莫司 免疫抑制 全角膜移植 tacrolimus allograft rejection total keratoplasty
  • 相关文献

参考文献12

二级参考文献48

  • 1陈家祺 杜念祖 等.全角膜带环形板层巩膜瓣移植术28例初步报告[J].中华眼科杂志,1985,21:271-271.
  • 2Waldock A, Cook SD. Corneal transplantation: how successful are we? Br J Ophthalmol, 2000, 84: 813-815.
  • 3Bertelmann E, Jaroszewski J, Pleyer UWE. Corneal allograft rejection: current understanding. 2. Clinical implications. Ophthalmologica, 2002, 216: 2-12.
  • 4Neubaus P, Klupp J, Langrebr JM. mTOR inhibitors: an overview. Liv Transplanta, 2001, 7:473-484.
  • 5Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation, 2001, 72: 1181-1193.
  • 6Holland EJ, Chan CC, Wetzig RP, et al. Clinical and immunohistologic studies of corneal rejection in the rat penetrating keratoplasty model. Cornea, 1991, 10: 374-380.
  • 7Niederkorn JY. Mechanisms of corneal graft rejection: the sixth annual thygeson lecture, presented at the ocular microbiology and immunology group meeting, October 21, 2000. Cornea, 2001, 20: 675-679.
  • 8MacDonald AS. A worldwide, phase Ⅲ, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation, 2001, 71: 271-280.
  • 9Tian L, Lu L, Yuan Z, et al. Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery. Transplantation, 2004, 77:183-189.
  • 10Ghosh P, Buchholz MA, Yano S, et al. Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway. Blood, 2002, 99: 4517-4524.

共引文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部